Lumos Pharma, Inc. (LUMO)
Dec 12, 2024 - LUMO was delisted (reason: acquired by Double Point Ventures)
4.340
0.00 (0.00%)
Inactive · Last trade price on Dec 11, 2024

Company Description

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases.

Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.

The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease.

Lumos Pharma, Inc. is headquartered in Austin, Texas.

Lumos Pharma, Inc.
Lumos Pharma logo
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees33
CEORichard Hawkins

Contact Details

Address:
4200 Marathon Boulevard, Suite 200
Austin, Texas 78756
United States
Phone512 215 2630
Websitelumos-pharma.com

Stock Details

Ticker SymbolLUMO
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001126234
CUSIP Number55028X109
ISIN NumberUS55028X1090
Employer ID42-1491350
SIC Code2834

Key Executives

NamePosition
Richard J. HawkinsFounder, Chief Executive Officer and Chairman
Dr. John C. McKew Ph.D.Chief Scientific Officer and President
Lori D. Lawley CPAChief Financial Officer and Principal Accounting Officer
Lisa Wells MillerSenior Director of Investor Relations
Bradley J. Powers J.D.Chief Compliance Officer and General Counsel
Aaron Schuchart B.B.A., CPA, M.B.A.Chief Business Officer
Dr. Pisit Pitukcheewanont FAAP, M.D.Chief Medical Officer
Alpa ParikhSenior Vice President of CMC and Supply Management
Eddie L. Varnado M.B.A.Corporate Controller

Latest SEC Filings

DateTypeTitle
Dec 13, 2024AWAmendment Withdrawal Request
Dec 12, 2024EFFECTNotice of Effectiveness
Dec 12, 2024EFFECTNotice of Effectiveness
Dec 12, 2024EFFECTNotice of Effectiveness
Dec 12, 2024EFFECTNotice of Effectiveness
Dec 12, 2024EFFECTNotice of Effectiveness
Dec 12, 2024POS AMPost-Effective amendments for registration statement
Dec 12, 2024POS AMPost-Effective amendments for registration statement
Dec 12, 2024POS AMPost-Effective amendments for registration statement
Dec 12, 2024POS AMPost-Effective amendments for registration statement